The patent term for Namenda has been extended through April 10, 2015, according to Forest Laboratories. The medication is used to help treat people with Alzheimer’s disease. The patent had earlier ...

The drug memantine is a safe and effective therapy that helps patients suffering from moderate to severe Alzheimer disease for up to a year. However, evidence that the drug might slow the underlying ...

Memantine, a drug typically used to treat symptoms of Alzheimer's disease (AD), is linked to a significant reduction in symptoms of trichotillomania and skin-picking disorder, new research shows.

NEW YORK (Reuters) - Purchasers of Allergan Plc's Namenda asked a federal judge on Tuesday to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the ...

WASHINGTON -- Americans with advanced Alzheimer's disease soon can try the first treatment proved effective for late stages of the mind-robbing illness. Memantine should be on pharmacy shelves by ...

The dementia drug memantine showed promise for improving social functioning in a small trial of youth with autism. Nine of 16 children and adolescents treated with memantine met the response criteria ...

Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) N-methyl ...

Memantine HCl 7mg, 14mg, 21mg, 28mg; ext-rel caps. Tabs—60; Titration Pak (28 x 5mg + 21 x 10mg)—1; Oral soln—contact supplier; XR caps 7mg, 21mg—30; 14mg, 28mg—30, 90; XR Titration Pak (7 x 7mg + 7 x ...

ATLANTA — Adding the Alzheimer drug memantine (Namenda, Allergan) to treatment with a selective serotonin reuptake inhibitor may improve depressive symptoms, executive function, and other outcomes in ...

(CN) - Actavis cannot maintain its billion-dollar monopoly on an Alzheimer's drug by forcing Alzheimer's patients to switch to a freshly patented version before a generic can enter the market, a 2nd ...

You have full access to this article via your institution. In June 2000, Merz and Forest announced a development and marketing agreement for memantine in the United States for the treatment of AD and ...